Overexpression of the p16
protein has been reported in
breast cancer and may trigger the secretion of
antibodies against itself. Circulating anti-p16
antibodies that were detected with a
recombinant protein have been reported in
breast cancer. The present study was designed to determine whether the levels of circulating
IgG antibody to p16
protein-derived linear
antigens are altered in
breast cancer. An
enzyme-linked
immunosorbent assay (ELISA) was developed in-house to determine circulating
IgG against
peptide antigens derived from the p16
protein in 152 female
breast cancer patients and 160 healthy female subjects. The Student's T-test revealed that
breast cancer patients exhibited significantly higher levels of anti-p16
IgG antibody compared to control subjects (T=2.02, P=0.045). In addition, ductal
cancer appeared to be the main type contributing to the increased levels of circulating anti-p16
antibodies (T=2.08, P=0.038). Of all four stages of
breast cancer, stage I was associated with the highest levels of
IgG antibody (T=2.02, P=0.045) and receiver operating characteristic (ROC) analysis demonstrated that the area under the ROC curve was 0.74 (95% confidence interval: 0.65-083) and that the sensitivity against a specificity of 90% was 30.3%. Therefore, the levels of circulating
IgG antibody to the p16
protein may be a potential
biomarker for early diagnosis of
breast cancer.